Company Cybin Inc.

Equities

CYBN

CA23256X1006

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nyse Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.35 ^USD	+1.16%		-4.81%	-14.63%

Apr. 17	Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	MT
Apr. 16	Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment	MT

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

Number of employees: 50

Managers	Title	Age	Since
Douglas Drysdale CEO	Chief Executive Officer	54	20-07-31
Paul Glavine FOU	Founder	35	16-10-12
Eric So FOU	Founder	49	16-10-12
Greg Cavers DFI	Director of Finance/CFO	54	20-11-04
Alex Nivorozhkin CTO	Chief Tech/Sci/R&D Officer	64	20-11-30
Ryan Richardson CTO	Chief Tech/Sci/R&D Officer	-	-
Amir Inamdar CTO	Chief Tech/Sci/R&D Officer	-	21-09-30
Alexander Belser CTO	Chief Tech/Sci/R&D Officer	-	20-09-30
Lori Challenger ADM	Chief Administrative Officer	-	-
Aaron Bartlone COO	Chief Operating Officer	-	20-11-30

Members of the board	Title	Age	Since
Eric So FOU	Founder	49	16-10-12
Mark Lawson BRD	Director/Board Member	52	20-11-04
Grant Froese BRD	Director/Board Member	62	20-11-04
Theresa Firestone BRD	Director/Board Member	-	21-08-15
George Tziras BRD	Director/Board Member	43	23-10-22
Eric Hoskins BRD	Director/Board Member	63	20-11-04
Paul Glavine FOU	Founder	35	16-10-12

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	759,692,495	709,079,609 ( 93.34 %)	0	93.34 %

Name	Equities	%	Valuation
RA Capital Management LP 14.15 %	58,139,535	14.15 %	24 M $
Deep Track Capital LP 14.15 %	58,139,535	14.15 %	24 M $
Point72 Asset Management LP 7.317 %	30,061,112	7.317 %	12 M $
Point72 Asset Management LP 7.317 %	30,061,112	7.317 %	12 M $
Peter David Rands 4.039 %	16,593,494	4.039 %	7 M $
Rosalind Advisors, Inc. 3.398 %	13,960,000	3.398 %	6 M $
Eric So 2.817 %	11,572,411	2.817 %	5 M $
Paul Glavine 2.736 %	11,242,407	2.736 %	5 M $
John Kanakis 2.608 %	10,715,410	2.608 %	4 M $
Anson Funds Management LP 2.172 %	8,924,494	2.172 %	4 M $

Name	Equities	%	Valuation
Greene Brett 14.35 %	144,353	14.35 %	59 762 $

Cybin, Inc.

100 King Street West Suite 5600

M5X 1C9, Toronto

http://www.cybin.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.4791 CAD

Average target price

6.568 CAD

Spread / Average Target

+1,270.73%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
CYBIN INC.	-14.63%	266M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs